Introduction
============

The use of economic evaluation in determining resource allocation is well established in a number of health services ([@b5]). There is growing recognition that a comprehensive economic assessment of a new healthcare intervention at the time of launch requires both cost-effectiveness analysis (CEA) and a budget impact analysis (BIA)

BIA for new pharmaceutical products provides estimates of the likely impact of the new drug on healthcare decision-makers short- and longer-term annual budgets. It is an essential part of a comprehensive economic assessment of a new pharmaceutical product and is increasingly required ([@b9]), along with CEA, before national or local formulary approval and/or reimbursement

National regulatory agencies such as the National Institute for Clinical Excellence (NICE) in England and Wales ([@b8]), the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia ([@b11]), the Co-ordinating OFFICE for Health Technology Assessment in Canada ([@b2]), the French Transparency Committee ([@b3]) and the Pharmaceutical Benefits Board in Sweden (Pharmaceuticals Benefits Board 2003) as well as managed care organizations (MCOs) in the USA, now require that companies submit estimates of both the cost-effectiveness and the likely impact of the new healthcare interventions on national or health plan budgets to support the reimbursement or formulary inclusion ([@b15]).

Standard methods for performing and presenting the results of CEAs are well accepted ([@b8]), but the same progress has not been made for BIAs ([@b7]). Several factors, which are not generally needed for CEA, should be part of a comprehensive BIA including the size of the treated population, incidence and prevalence estimations, and market penetration rates for the new drug as well as for the main comparators. A review of the recent literature indicates that there are only a limited number of published budget impact analyses ([@b1]) and these vary greatly in the methods used.

It is recommended that a comprehensive approach to budget impact estimation be adopted, with the results being presented from both a societal perspective as well as from more limited perspectives depending on the needs of the decision-maker.

Recently, [@b15] have proposed an initial framework for standardization of BIAs

This paper analyzes the potential impact of early retirement on healthcare payer's annual budgets due to a chronic and progressing disease such as diabetes mellitus. The study is first based on a theoretical analysis before a hypothetical new product in diabetes treatment is applied.

Materials and methods
=====================

The budget of a healthcare payer like the social insurance payers in Germany or the private ones in the US, for instance, are mainly dependent on their expenses as well as their revenues ([@b17]). The expenses are mainly dependent on the development of the diseases of the insureds and the related costs whereas the revenue is highly influenced by the premium an insured is paying. Once an insured is being (early) retired the real amount paid for premiums is much lower in comparison to the premiums when an insured is working full-time due to the lower income.

The following paragraph shows the theoretical impact of early retirement as well as the impact of the drug price on the equilibrium equation for a general health insurance. The next step is to analyze a hypothetical example with a diabetes population.

Methods
-------

The cost of illness, including the treatment costs as well as the complication costs due to a given disease, is the main driver on the healthcare payer budgets. The calculation of the cost of illness comprises the direct costs for complications (CoC) and the treatment costs (CoT) for the given diseases i in the years t, respectively (with i = 1, .., N and t = 1; ...; T). The costs of illness (CoI) for n patients are calculated according to the following equation [E1](#FD1){ref-type="disp-formula"}:
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Additionally it is assumed that the number of complications c as well as the severity s of these are the drivers for the CoC and the market share for product A MS~A~, with an influence of price for competitors p~A+1~, as well as the price p~A~ for the drugs A (A = 1, ..., Z) are the drivers for the CoI. Furthermore the numbers of patients n treated in the disease population i is mainly dependent on the prevalence i~p~ and incidence i~i~ of the disease as well as the mortality rates m~i~ within that population. The model is assumed to be dynamic, and hence with a higher mortality rate, fewer survivors have to be treated. Hence equation ([E1](#FD1){ref-type="disp-formula"}) can be rewritten as
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The revenue side R of a healthcare payer balance sheet is driven by the premiums h the n insureds are paying.
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It is furthermore supposed to take the net present value of all revenues into account. Assuming that the income Y of the insureds are influencing the real cash flow h of the revenue side and the mortality rates have an impact on the number of insureds, equation ([E3](#FD3){ref-type="disp-formula"}) can be rewritten as following
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Due to the nature of some diseases early retirement is widely spread in some population parts ([@b14]). Retirement r as a whole has a significant influence on the income Y of that population. Assuming that no other factors have an impact on the income level equation ([E4](#FD4){ref-type="disp-formula"}) can be adapted to ([E5](#FD5){ref-type="disp-formula"})
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For social insurance based systems such as the German healthcare system, the insurance companies are mainly non-profit organizations (with the exception of the private companies). Hence the premiums for the insureds are in an equilibrium (without a need for an increase) if the revenue of the payers is equal to the costs of these. Assuming that there is only one healthcare payer in a given country equations ([E2](#FD2){ref-type="disp-formula"}) and ([E5](#FD5){ref-type="disp-formula"}) represent the equilibrium of the healthcare payer company:
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To simplify the interpretation of ([E6](#FD6){ref-type="disp-formula"}) this is rewritten to equation ([E7](#FD7){ref-type="disp-formula"})
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First derivations with respect to retirement r and the drug price p for a new product c are as follows
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Equation ([E8](#FD8){ref-type="disp-formula"}) shows the following: When the retirement rate r changes, the income is also changed and this could be assumed to be negative. This assumption can be easily explained: Y decreases when r increases. Certainly in markets with perfect competition and private insurance this might even be assumed to be positive when assuming an increasing demand for a larger amount of insurance coverage, whereas this assumption might even not be assumed in the most liberal healthcare market, the US, where elderly people or retired people are usually then covered by MediCare and no more by competing healthcare plans.

When the retirement rate r is increasing the real income will be decreased. The second part of [equation E8](#FD8){ref-type="disp-formula"} is showing the impact of income Y on the premium function h, which could be positive: Due to the higher income it is assumed that the real amount of premiums is increasing, when assuming such a healthcare system as the one in Germany where a decreasing revenue side can be assumed with an increasing retirement rate.

In equation ([E9](#FD9){ref-type="disp-formula"}) it is analyzed in which way a new product with price p~i~ has an influence on the insurance equilibrium equation ([E7](#FD7){ref-type="disp-formula"}). The number of patients n is decreasing the right-hand side of the equilibrium function ([E7](#FD7){ref-type="disp-formula"}) due to the sign of the first derivative. Additionally the costs of treatment CoT~A~ are of interest, whereas the sign here is mainly dependent on the price level as well as on the market share MS~A~ (first two parts in the bracket). Furthermore the change in costs of treatment and market share of the comparators of product A, namely A−1 and A+1, have an influence on the sign of that first derivative. Hence the sign of this equation is not clear and has to be analyzed case by case. The sign is mainly dependent on the price level of the comparator drugs and their market share. These findings are only valid for the case *A* ≠ 1 and *A* ≠ *Z*. One special case is an innovative product without any comparators (A = 1). Then the costs of treatment are changing with the price (increase) and the whole first derivative with respect to p~i~ is becoming negative. This would then have an influence on the revenue side which has to be increased to still fulfill the equilibrium criteria in equation ([E7](#FD7){ref-type="disp-formula"})

Results
=======

After the theoretical analysis of an impact of early retirement and also price changes for a product A, a hypothetical comparison follows. The market i is assumed to be the one for type 2 diabetes mellitus patients. The comparison is based on the epidemiological finding of the UKPDS, where glycemic control was analyzed with the options of diet, sulfonylurea, metformin, and insulin therapy ([@b16]).

In a usual budget impact analysis two scenarios are compared, which are usually assumed to be a world with the new possible treatment option and other available treatments and one without that new option, which is usually the environment of the current market. The market share is changed due to the fact that this new option will be available on the market.

For this hypothetical analysis it is assumed that a pharmaceutical company will develop an innovation of a so-called oral antidiabetic (OADs), which is assumed to be more effective in comparison with the OADs currently available on the market. However, the insulins are still the state of the art after OADs are no more working properly in the patients in terms of HbA1c adjustment.

For the following analysis direct costs for various diabetes complications were derived from [@b10] whereas it was directly assumed that these US data could also be valid for the German circumstance (see [Table 1](#tbl1){ref-type="table"}). Prevalence data as well as early retirement data were derived from literature ([@b14]). The main assumptions for this analysis are summarized in [Table 2](#tbl2){ref-type="table"}. Assumed complication rates derived from UKPDS 33 are summarized in [Table 3](#tbl3){ref-type="table"}. The market for diabetes was assumed to consist just of insulin drugs and oral antidiabetics (OADs). The efficacy of the hypothetical new option on the market was assumed to be 20% better in terms of outcomes in comparison with the standard OADs. Hence the following two scenarios are analyzed: The world without the new option with the market share distribution in the following way. 38% of patients are getting a subcutaneous insulin and the rest of the treated patients are getting the OADs. All other patient groups treated with any other possibility are not taken into account. The market share over time is changed in the way that the insulin market will have a market share of 40% after 1 year and hence the OAD market is declining by that amount. The world with the new option has the same starting point for the insulin and the OADs, whereas the new option is assumed to have no market share at all. The following three scenarios (defined on the view of a pharmaceutical company) are analyzed for the comparator world including the hypothetical new treatment ([Table 4](#tbl4){ref-type="table"}):

-   Base Case: The retirement rate was assumed to be 5% for both scenarios. Additionally the following market shares were assumed:

1.  ◦ Market share for insulin after 4 years: 45%

2.  ◦ Market share for OADs after 8 years: 10%

3.  ◦ Market share for the new option after 8 years: 45%

-   Best Case: The retirement rate was assumed to be 2.5% for both scenarios. Additionally the following market shares were assumed:

1.  ◦ Market share for insulin after 4 years: 30%

2.  ◦ Market share for OADs after 8 years: 0%

3.  ◦ Market share for the new option after 8 years: 70%

-   Worst Case: The retirement rate was assumed to be 7.5% for both scenarios. Additionally the following market shares were assumed:

1.  ◦ Market share for insulin after 4 years: 50%

2.  ◦ Market share for OADs after 8 years: 31%

3.  ◦ Market share for the new option after 8 years: 19%

###### 

Base assumptions for the three budget impact scenarios

  Parameter                                                               Base case scenario   Best case scenario   Worst case scenario
  ----------------------------------------------------------------------- -------------------- -------------------- ---------------------
  Average yearly income (€)[a](#tf1-1){ref-type="table-fn"}               35,517               35,517               35,517
  Average yearly income lost due to early retirement (€)                  14,207               14,207               14,207
  Retirement rate for current Tx (%)                                      5.0                  5.0                  5.0
  Retirement rate for current Tx and new option (%)                       5.0                  2.5                  7.5
  Premium (percentage of yearly income)[a](#tf1-1){ref-type="table-fn"}   14.0                 14.0                 14.0
  Covered population - in both arms                                       83,000,000           83,000,000           83,000,000
  Number of treated patients[a](#tf1-1){ref-type="table-fn"}              107,070              107,070              107,070
  Prevalence (%)[a](#tf1-1){ref-type="table-fn"}                          6.45                 6.45                 6.45
  Incidence per year                                                      1,000                500                  2,000

in the "Current Tx" and "Current Tx & NEW option" arm.

###### 

Diabetes-related complication costs derived from literature

  Cost item                     Costs per event (€)   Source
  ----------------------------- --------------------- ----------------------------
  Hypoglycemia                  384                   *Diabetes Care* 1995
  Retinopathy/Macular edema     71                    [@b10]
  Blindness in one eye          4365                  [@b10]
  Cataract                      2250                  Internal expert assumption
  Micro-/Macroalbuminuria       78                    [@b10]
  End-stage renal disease       77,735                [@b10]
  Neuropathy                    273                   [@b10]
  Peripheral arterial disease   6867                  DRG handbook 2000
  Diabetic foot syndrome        3421                  [@b10]
  Myocardial infarction         34,597                [@b10]
  Heart failure                 12,038                DRG handbook 2000
  Angina pectoris               3102                  [@b10]
  Stroke                        50,858                [@b10]

###### 

Cumulative diabetes complication rates derived from [@b16] for the world with and without the new option ("Current treatment" vs "Current treatment & NEW option"). The complication rates are reported for the hypothetical diabetes cohort of 107,070 at year 0 (see assumptions)

  Complication                                                                     "Current treatment"                                                                                                               
  -------------------------------------------------------------------------------- ------------------------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------ -------------
  Hypoglycemia                                                                     2478                      5274         7257         8861         10,060       11,087       11,782       12,331       12,772       10,649
  Ophthalmic disorders (retinopathy, macular edema, blindness, cataract)           12,376                    23,052       31,963       39,641       46,598       52,785       58,389       63,589       68,376       72,850
  Kidney system, (Micro-, macroalbuminuria, end-stage renal disease)               4835                      9460         14,175       18,373       22,431       26,438       30,321       33,827       37,141       39,842
  Nerve system (neuropathy, peripheral arterial disease, diabetic foot syndrome)   4613                      9042         13,571       18,124       22,578       26,874       30,963       35,442       40,158       44,560
  Cardiovascular system                                                            3094                      58839        8651         11,365       14,038       16,619       19,142       21,398       23,713       26,014
  Mortality                                                                        5845                      11,442       16,574       21,279       25,920       30,118       34,032       37,834       41,378       44,782
                                                                                                                                                                                                                     
  **Complication**                                                                 **"Current treatment"**                                                                                                           
                                                                                                                                                                                                                     
                                                                                   **Year 1**                **Year 2**   **Year 3**   **Year 4**   **Year 5**   **Year 6**   **Year 7**   **Year 8**   **Year 9**   **Year 10**
                                                                                                                                                                                                                     
  Hypoglycemia                                                                     2831                      5092         6999         8688         9876         10,945       11,672       12,279       12,915       13,387
  Ophthalmic disorders (retinopathy, macular edema, blindness, cataract)           11,513                    21,403       29,638       36,704       43,064       48,508       53,467       58,008       62,184       66,029
  Kidney system (Micro-, macroalbuminuria, end-stage renal disease)                4460                      8687         12996        16872        20,596       24,244       27,787       30,993       34,047       36,536
  Nerve system (neuropathy, peripheral arterial disease, diabetic foot syndrome)   4286                      8348         12,423       16,517       20,489       24,283       27,819       31,706       35,773       39,509
  Cardiovascular system                                                            2931                      5564         8180         10,722       13,251       15,717       18,076       20,173       22,303       24,419
  Mortality                                                                        5484                      10,732       15,519       19,979       24,438       28,395       32,121       35,824       39,304       42,625

###### 

Market share for the three possible treatments over time for the three budget impact scenarios

  Market share share                                    Current market share   Target market share (Base / Best / Worst)   Time to reach the target
  ----------------------------------------------------- ---------------------- ------------------------------------------- --------------------------
  Insulin: Current Tx[a](#tf4-1){ref-type="table-fn"}   38                     40                                          1
  OADs: Current Tx[a](#tf4-1){ref-type="table-fn"}      62                     60                                          1
  Insulin: Current Tx + new option                      38                     45 / 30 / 50                                4
  OADs: Current Tx + new option                         62                     10 / 0 / 31                                 8
  New option                                            0                      45 / 70 / 19                                8

Assumption: fixed market in terms of scenarios.

The price for subcutaneous insulin was assumed to be €89, for the OADs €286 (see [Table 5](#tbl5){ref-type="table"}). The base, best, and worst case analyses were run within some stratification groups for the incidence cases and drug costs for the new option (see [Table 1](#tbl6){ref-type="table"}).

###### 

Yearly drug costs (€) for the three pharmaceutical treatment options on the market

  Cost item (€; yearly)       Base case scenario   Best case scenario   Worse case scenario
  --------------------------- -------------------- -------------------- ---------------------
  Insulin                     286                  286                  286
  Oral antidiabetics (OADs)   89                   89                   89
  New option                  1,000                500                  1,500

The budget impact for the base case analysis, 1000 incident cases and drug costs of €500, ranged from €58,860,034 (best case) to €99,108,673 (base case) cumulative after 10 years ([Table 7](#tbl7){ref-type="table"}). Assuming that the premium assumption of 14% p.a. was an equilibrium of the costs and the expenses (see [equation E7](#FD7){ref-type="disp-formula"}) the difference between the yearly premiums of the world with and without the hypothetical new drug ranged between 0.0034 and 0.0122, which was a proportional difference between 2.3% and 8.9% after 10 years. It turned out that the direction of the difference of the yearly premiums and the budget impact result would influence the decision makers in the same way. The new treatment option is not only more effective and has a positive impact on the healthcare payer's budget (in terms of cost reduction), but has also a reduction in the yearly premiums as a result due to the improvement of the early retirement rate. This conclusion can also be drawn for the third sensitivity analyses (drug price: €1500). The only scenario where the hypothetical new drug is dominant in terms of budget impact and premium change is the analysis with an assumed drug price of €500

###### 

Budget Impact and premium differences for the three scenarios (base, best worse case) and for the corresponding (new option) cost groups for the incidence group 500 patients per year. Budget Impact as well as premium differences are "Current Tx" vs "Current Tx & NEW"

  Incidence per year: 500              Year 1         Year 2         Year 3         Year 4         Year 5         Year 6         Year 7         Year 8         Year 9         Year 10
  ------------------------------------ -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------------
  New option costs: €500                                                                                                                                                      
                                                                                                                                                                              
  Budget Impact: Base Case             8,322,292      13,200,602     22,984,763     33,912,459     41,579,302     46,191,844     56,745,854     66,153,332     79,673,949     92,831,737
  Budget Impact: Best Case             4,602,027      4,602,027      10,534,066     17,851,526     21,533,668     21,958,321     28,711,182     34,008,745     43,735,848     52,583,097
  Budget Impact: Worse Case            6,592,285      11,508,759     19,174,141     27,452,510     33,824,149     38,376,653     46,298,925     53,653,656     63,340,817     73,035,440
  Premium difference (%): Base Case    0.0013 (0.9)   0.0028 (1.8)   0.0045 (2.8)   0.0059 (3.6)   0.007 (4.3)    0.0081 (5.0)   0.0088 (5.6)   0.0089 (5.8)   0.0087 (5.9)   0.0084 (6.0)
  Premium difference (%): Best Case    0.0023 (1.6)   0.0045 (2.9)   0.0068 (4.3)   0.0086 (5.4)   0.0102 (6.4)   0.0116 (7.4)   0.0127 (8.1)   0.0127 (8.5)   0.0125 (8.7)   0.0121 (8.8)
  Premium difference (%): Worse Case   0.0001 (0.0)   0.0008 (0.5)   0.0015 (0.9)   0.0021 (1.3)   0.0026 (1.6)   0.0031 (1.9)   0.0034 (2.1)   0.0035 (2.2)   0.0034 (2.2)   0.0032 (2.2)
                                                                                                                                                                              
  New option costs: €1,000                                                                                                                                                    
                                                                                                                                                                              
  Budget Impact: Base Case             −11,008,614    −26,002,120    −36,453,342    −46,000,992    −58,886,072    −74,875,789    −85,752,481    −98,107,186    −107,540,589   −118,061,822
  Budget Impact: Best Case             −28,738,462    −62,009,423    −89,219,944    −114,620,480   −143,187,163   −174,725,971   −200,609,303   −228,166,314   −252,589,238   −278,662,119
  Budget Impact: Worse Case            −513,781       −2,475,995     −1,671,224     −372,342       −1,138,886     −3,899,416     −3,928,150     −4,886,497     −4,197,019     −3,927,155
  Premium difference (%): Base Case    0.0013 (0.9)   0.0028 (1.8)   0.0046 (2.8)   0.0061 (3.7)   0.0076 (4.4)   0.0092 (5.3)   0.0104 (6.0)   0.0111 (6.4)   0.0115 (6.6)   0.0117 (6.8)
  Premium difference (%): Best Case    0.0023 (1.6)   0.0045 (2.9)   0.0069 (4.3)   0.009 (5.5)    0.011 (6.6)    0.013 (7.7)    0.0148 (8.7)   0.0158 (9.3)   0.0164 (9.7)   0.0167 (10.0)
  Premium difference (%): Worse Case   0.0001 (0.0)   0.0008 (0.5)   0.0016 (0.9)   0.0022 (1.3)   0.0028 (1.6)   0.0036 (2.0)   0.0041 (2.3)   0.0044 (2.4)   0.0046 (2.5)   0.0046 (2.6)
                                                                                                                                                                              
  New option costs: €1,500                                                                                                                                                    
                                                                                                                                                                              
  Budget Impact: Base Case             −30,339,519    −65,176,386    −95,691,990    −125,316,374   −158,228,845   −194,222,406   −225,112,588   −257,516,882   −287,111,454   −318,067,899
  Budget Impact: Best Case             −61,920,432    −128,613,390   −188,842,320   −246,641,851   −307,072,176   −370,175,648   −427,511,437   −486,532,420   −542,643,841   −600,872,385
  Budget Impact: Worse Case            −7,619,847     −16,434,486    −22,363,688    −27,761,139    −35,280,174    −44,879,832    −51,912,247    −60,000,445    −66,465,838    −73,438,798
  Premium difference (%): Base Case    0.0013 (0.9)   0.0028 (1.8)   0.0046 (2.8)   0.0061 (3.7)   0.0076 (4.4)   0.0092 (5.3)   0.0104 (6.0)   0.0111 (6.4)   0.0115 (6.6)   0.0117 (6.8)
  Premium difference (%): Best Case    0.0023 (1.6)   0.0045 (2.9)   0.0069 (4.3)   0.009 (5.5)    0.1104 (6.6)   0.0131 (7.7)   0.0148 (8.7)   0.0158 (9.3)   0.0164 (9.7)   0.0167 (10.0)
  Premium difference (%): Worse Case   0.0001 (0.0)   0.0008 (0.5)   0.0016 (0.9)   0.0022 (1.3)   0.0028 (1.6)   0.0036 (2.0)   0.0041 (2.3)   0.0044 (2.4)   0.0046 (2.5)   0.0046 (2.6)

The second analysis was done by taking the same assumptions as before but changing the incidence rate from 1000 new cases per year to 500 new cases per year. For the base case analysis (drug costs €500) it can be seen that the budget impact is negative which means that the current treatment possibilities (insulin and OADs) are cheaper than the current treatment inclusive of the hypothetical new treatment (see [Table 6](#tbl6){ref-type="table"}). But when reviewing the yearly premiums based on the early retirement rate and the costs per year, the decision-maker should go with the new treatment due to lower yearly premiums, between 0.0046 (proportional: 2.6%) and 0.0167 (proportional: 10.0%). The same conclusion can be drawn when doing the analysis for a yearly drug price per patient of €1500. Interestingly the influence on the decision-maker is changed when including a drug price for the hypothetical new option to €500. With that price the budget impact is improved in terms of cost reduction with the new treatment as well as a lower premium per year.

###### 

Budget Impact and premium differences for the three scenarios (base, best worse case) and for the corresponding (new option) cost groups for the incidence group 1000 patients per year. Budget Impact as well as premium differences are "Current Tx" vs "Current Tx & NEW"

  Incidence per year: 1,000            Year 1         Year 2         Year 3         Year 4         Year 5         Year 6         Year 7         Year 8         Year 9         Year 10
  ------------------------------------ -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- --------------
  New option costs: €500                                                                                                                                                      
                                                                                                                                                                              
  Budget Impact: Base Case             8,8847,518     14,172,088     24,553,377     36,123,442     44,348,912     49,426,880     60,670,863     70,756,833     85,102,459     99,108,673
  Budget Impact: Best Case             4,968,733      5,573,514      12,102,680     20,062,508     24,303,277     25,193,357     32,636,192     38,612,245     49,164,357     58,860,034
  Budget Impact: Worse Case            7,117,511      12,480,246     20,742,754     29,663,493     36,593,758     41,611,688     50,223,934     58,257,157     68,769,327     79,312,377
  Premium difference (%): Base Case    0.0013 (0.1)   0.0028 (1.8)   0.0045 (2.9)   0.0059 (3.7)   0.0071 (4.4)   0.0082 (5.1)   0.0089 (5.7)   0.0091 (5.9)   0.0088 (6.0)   0.0085 (6.1)
  Premium difference (%): Best Case    0.0024 (1.6)   0.0045 (3.0)   0.0068 (4.4)   0.0087 (5.5)   0.0103 (6.5)   0.0118 (7.5)   0.0127 (8.2)   0.0129 (8.6)   0.0126 (8.8)   0.0122 (8.9)
  Premium difference (%): Worse Case   0.0001 (0.1)   0.0008 (0.5)   0.0016 (1.0)   0.0022 (1.3)   0.0027 (1.6)   0.0032 (2.2)   0.0036 (2.3)   0.0036 (2.3)   0.0035 (2.3)   0.0034 (2.3)
                                                                                                                                                                              
  New option costs: €1,000                                                                                                                                                    
                                                                                                                                                                              
  Budget Impact: Base Case             −11,008,614    −26,070,717    −36,652,501    −46,415,326    −59,806,876    −76,750,125    −88,377,410    −101,887,136   −112,177,201   −123,979,141
  Budget Impact: Best Case             −28,738,462    −62,164,812    −89,744,421    −115,808,158   −145,612,915   −179,171,899   −207,231,445   −237,830,339   −265,435,969   −295,744,857
  Budget Impact: Worse Case            −513,781       −2,483,397     −1,653,996     −279,004       −1,012,490     −3,858,233     −3,693,205     −4,510,308     −3,303,420     −2,494,335
  Premium difference (%): Base Case    0.0013 (0.8)   0.0028 (1.8)   0.0045 (2.8)   0.0059 (3.6)   0.007 (4.3)    0.0081 (5.0)   0.0088 (5.6)   0.0089 (5.8)   0.0087 (5.9)   0.0084 (6.0)
  Premium difference (%): Best Case    0.0023 (1.6)   0.0045 (2.9)   0.0068 (4.3)   0.0086 (5.4)   0.0102 (6.4)   0.0116 (7.4)   0.0125 (8.1)   0.0127 (8.5)   0.0125 (8.7)   0.0121 (8.8)
  Premium difference (%): Worse Case   0.0001 (0.0)   0.0008 (0.5)   0.0015 (0.9)   0.0021 (1.3)   0.0026 (1.6)   0.0031 (1.9)   0.0034 (2.1)   0.0035 (2.2)   0.0034 (2.2)   0.0032 (2.2)
                                                                                                                                                                              
  New option costs: €1500                                                                                                                                                     
                                                                                                                                                                              
  Budget Impact: Base Case             −30,339,519    −65,342,035    −96,289,765    −126,743,112   −161,193,055   −199,692,095   −233,500,675   −269,927,604   −304,028,352   −340,790,018
  Budget Impact: Best Case             −61,920,432    −128,931,651   −190,022,909   −249,467,842   −312,759,498   −380,302,119   −443,174,072   −509,669,424   −574,607,786   −644,072,811
  Budget Impact: Worse Case            −7,619,847     −16,475,553    −22,482,132    −28,010,518    −35,849,128    −46,093,119    −53,685,334    −62,674,272    −69,947,658    −78,024,111
  Premium difference (%): Base Case    0.0013 (0.9)   0.0028 (1.8)   0.0045 (2.8)   0.0059 (3.6)   0.007 (4.3)    0.0081 (5.0)   0.0088 (5.6)   0.0089 (5.8)   0.0087 (5.9)   0.0084 (6.0)
  Premium difference (%): Best Case    0.0023 (1.6)   0.0045 (2.9)   0.0068 (4.3)   0.0086 (5.4)   0.0102 (6.4)   0.0116 (7.4)   0.0125 (8.1)   0.0127 (8.5)   0.013 (8.7)    0.0121 (8.8)
  Premium difference (%): Worse Case   0.0001 (0.0)   0.0008 (0.9)   0.0015 (0.9)   0.0021 (1.3)   0.0026 (1.6)   0.0032 (1.9)   0.0034 (2.1)   0.0035 (2.2)   0.0034 (2.2)   0.0032 (2.2)

The third analysis was run for the three scenarios described above and an incidence rate of 2000 new cases per year (see [Table 8](#tbl8){ref-type="table"}). Also for this stratification analysis it turns out that the impact of the early retirement rate is much higher for the yearly premium calculations than for the budget impact. The budget impact would speak in favor of the new hypothetical treatment for a price of €500 but not for the other two price options, whereas the premiums calculations would always lead to the conclusion that the new treatment should be reimbursed by the healthcare payer.

###### 

Budget Impact and premium differences for the three scenarios (base, best worse case) and for the corresponding (new option) cost groups for the incidence group 2,000 patients per year. Budget Impact as well as premium differences are "Current Tx" vs "Current Tx & NEW"

  Incidence per year: 2000             Year 1         Year 2         Year 3         Year 4         Year 5         Year 6         Year 7         Year 8         Year 9         Year 10
  ------------------------------------ -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------------
  New option costs: €500                                                                                                                                                      
                                                                                                                                                                              
  Budget Impact: Base Case             8,322,292      13,257,513     23,383,676     35,108,597     43,824,505     49,633,878     63,022,311     75,854,974     94,961,295     114,606,698
  Budget Impact: Best Case             4,443,507      4,616,994      10,797,333     18,752,795     23,205,302     24,427,551     33,547,884     41,626,652     56,276,813     70,652,998
  Budget Impact: Worse Case            6,592,285      11,561,286     19,479,943     28,324,620     35,467,645     40,931,960     50,784,880     60,506,065     73,878,853     87,937,344
  Premium difference (%): Base Case    0.0013 (0.9)   0.0028 (1.8)   0.0043 (2.8)   0.0053 (3.5)   0.006 (4.1)    0.0065 (4.6)   0.0066 (5.0)   0.0062 (5.1)   0.0057 (5.0)   0.0051 (5.0)
  Premium difference (%): Best Case    0.0023 (1.6)   0.0044 (2.9)   0.0065 (4.2)   0.0079 (5.3)   0.0088 (6.1)   0.0094 (6.9)   0.0095 (7.3)   0.009 (7.5)    0.0082 (7.4)   0.0074 (7.4)
  Premium difference (%): Worse Case   0.0001 (0.0)   0.0007 (0.5)   0.0014 (0.9)   0.0019 (1.2)   0.0022 (1.4)   0.0025 (1.7)   0.0025 (1.9)   0.0024 (1.9)   0.0021 (1.8)   0.0019 (1.8)
                                                                                                                                                                              
  New option costs: €1,000                                                                                                                                                    
                                                                                                                                                                              
  Budget Impact: Base Case             −11,008,614    −26,002,120    −36,453,342    −46,000,992    −58,886,072    −74,875,789    −85,752,481    −98,107,186    −107,540,589   −118,061,822
  Budget Impact: Best Case             −28,738,462    −62,009,423    −89,219,944    −114,620,480   −143,187,163   −174,725,971   −200,609,303   −228,166,314   −252,589,238   −278,662,119
  Budget Impact: Worse Case            −513,781       −2,475,995     −1,671,224     −372,342       −1,138,886     −3,899,416     −3,928,150     −4,886,497     −4,197,019     −3,927,155
  Premium difference (%): Base Case    0.0013 (0.9)   0.0028 (1.8)   0.0046 (2.8)   0.0061 (3.7)   0.0076 (4.4)   0.0092 (5.3)   0.0104 (6.0)   0.0111 (6.4)   0.0115 (6.6)   0.0117 (6.8)
  Premium difference (%): Best Case    0.0023 (1.6)   0.0045 (2.9)   0.0069 (4.3)   0.009 (5.5)    0.011 (6.6)    0.0131 (7.7)   0.0148 (8.7)   0.0158 (9.3)   0.0164 (9.7)   0.0167 (10.0)
  Premium difference (%): Worse Case   0.0001 (0.0)   0.0016 (0.9)   0.0022 (1.3)   0.0028 81.6)   0.0036 (2.0)   0.0041 (2.3)   0.0044 (2.3)   0.0044 (2.4)   0.0046 (2.5)   0.0046 (2.6)
                                                                                                                                                                              
  New option costs: €1,500                                                                                                                                                    
                                                                                                                                                                              
  Budget Impact: Base Case             −30,339,519    −65,176,386    −95,691,990    −125,316,374   −158,228,845   −194,222,406   −225,112,588   −257,516,882   −287,111,454   −318,067,899
  Budget Impact: Best Case             −61,920,432    −128,613,390   −188,842,320   −246,641,852   −307,072,176   −370,175,648   −427,511,437   −486,511,437   −542,643,841   −600,872,385
  Budget Impact: Worse Case            −7,920,432     −16,434,486    −22,363,688    −27,761,139    −35,280,174    −44,897,832    −51,912,247    −60,000,445    −66,465,838    −73,438,798
  Premium difference (%): Base Case    0.0013 (0.9)   0.0028 (1.8)   0.0046 (2.8)   0.0061 (3.7)   0.0076 (4.4)   0.0092 (5.3)   0.0104 (6.0)   0.0111 (6.4)   0.0115 (6.6)   0.0117 (6.8)
  Premium difference (%): Best Case    0.0023 (1.6)   0.0045 (2.9)   0.0069 (4.3)   0.009 (5.5)    0.011 (6.6)    0.0131 (7.7)   0.0148 (8.7)   0.0158 (9.3)   0.0164 (9.7)   0.0167 (10.0)
  Premium difference (%): Worse Case   0.0001 (0.0)   0.0008 (0.5)   0.0016 (0.9)   0.0022 (1.3)   0.0028 (1.6)   0.0036 (2.0)   0.0041 (2.3)   0.0044 (2.4)   0.0046 (2.5)   0.0046 (2.6)

Discussion
==========

The dependency of healthcare payers on their revenue based on the premiums paid by their insured population and the costs mainly influenced by the cost of complications and the costs of treatment (pharmaceutical costs) was analyzed within a budget impact modeling framework. Across the ISPOR members of the Budget Impact Analysis Task Force there is currently no consensus on whether the revenue side of the healthcare payers should also be taken into account within a budget impact analysis ([@b6]). This study shows the theoretical implications of a new product if a change in the early retirement rate could be expected for a new product due to a higher efficacy in comparison with the standard treatment. The product price as well as the assumptions for the early retirement rate can change the equilibrium of a revenue-cost premium calculation for a healthcare payer as was derived in a theoretical model. Additionally a hypothetical comparison in diabetes patients was undergone. The theoretical results could be proved by this study. Some assumptions had to be done, for instance on the levels of drug prices, incidence and prevalence rates, as well as the event rates for some complications which were derived from a well-known study ([@b16]). In general it turned out that the premium differences were always in favor of the new option opportunity, which could be due to the assumption of a 20% better influence on the complications. The negative influence of the new option in terms of budget impact was highly dependent on the assumed drug price and the early retirement rate.

The weakness of this theoretical study can be seen in the following points. The premium calculations are usually based on all diseases and hence on all patients as well as on the disease-free population of the given healthcare payer. Within this hypothetical example it was assumed that only one disease area (diabetes) was of interest when analyzing the impact on the annual premiums. It was assumed that the impact of all other diseases as well as the impact of the healthy population is hold constant when comparing the two worlds of interest: Current treatment versus current treatment and new option. Additionally the impact of these groups was assumed to be constant over time and hence no new drugs would enter the market for other diseases from which a healthcare payer could benefit. Also, the early retirement rates were held constant over time, which means the impact of the new drug option and also the higher early retirement risk with a higher age were not taken into account. Within such a circumstance it can be seen that a new drug with a higher efficacy could lead to a benefit for the healthcare payer with two possibilities: On the one hand the new treatment possibility could reduce the costs and could hence result in an improvement for the budget impact for some scenarios, and on the other hand, which could go along with the budget impact argument, the new drug could lower the complication rates which would reduce the complication costs and the early retirement rate. The last point could lead to a possible decrease in the annual premiums due to a higher revenue. This last option is not only valid assuming a non-profit healthcare payer like the social insurance companies in Germany, for instance, but also for private insurance companies looking for profits. For the latter the profitability would increase by the difference of the annual premiums. The framework suggested here should be taken into account if there is any possibility of early retirement reduction due to a more effective treatment possibility. It is recommended that sensitivity analysis are not only done with the costs but also with the market share over time as well as with the incidence rates, based on epidemiological data. Further empirical research on the influence of premiums and costs on the decision-making process should be undertaken.

Preliminary results of this study were presented at the European congress of the Society for Medical Decision Making 2006 in Birmingham.
